Abemaciclib plus endocrine therapy for hormone receptor- positive, HER2-negative, node-positive, high-risk, early breast cancer

被引：1
|
作者：
Nozawa, Kazuki [1 ]
Sawaki, Masataka [1 ]
Iwata, Hiroji [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 4648681, Japan
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 03期
关键词：
OPEN-LABEL;
D O I：
10.1016/S1470-2045(23)00014-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E103 / E103
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [22] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience
    Battisti, Nicolo Matteo Luca
    Morrison, Laura
    Nash, Tamsin
    Senthivel, Nishanti
    Kestenbaum, Samantha
    Begum, Parvin
    Obeid, Mariam
    Hayhurst, William
    Yang, Dorothy
    Gafoor, Shafiah
    Brown, Caroline
    Rehman, Farah
    Kenny, Laura
    Hatcher, Olivia
    Susan, Susan
    Williams, Jennet
    Brown, Anna
    Rozati, Hamoun
    Alexandros, Alexandros
    Sawyer, Elinor
    Gousis, Charalampos
    Karapanagiotou, Eleni
    Rigg, Anna
    Rapti, Kleopatra
    Roylance, Rebecca
    Beresford, Mark
    Gee, Abigail L.
    Konstantis, Apostolos
    King, Judy
    Nathan, Mark
    Spurrell, Emma
    Pearce, Mark
    Bradwell, Dane
    Denton, Arshi
    Swain, Kate
    McGrath, Sophie
    Allen, Mark
    Ring, Alistair
    Johnston, Stephen
    Raja, Fharat
    CANCER RESEARCH, 2022, 82 (04)
  • [24] Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, Sara M.
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    McIntyre, Kristi
    Wei, Ran
    Munoz, Maria
    San Antonio, Belen
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Harbeck, Nadia
    EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [25] Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy
    Kaufman, Peter A.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Andre, Valerie
    Stoffregen, Clemens
    Shekarriz, Sarah
    Price, Gregory L.
    Carter, Gebra Cuyun
    Sledge, George W.
    ONCOLOGIST, 2020, 25 (02): : E243 - E251
  • [26] Long-term Patient-reported Outcomes from monarchE: Abemaciclib plus Endocrine Therapy for Adjuvant HR+, HER2-, Node-positive, High-risk, Early Breast Cancer
    Harbeck, Nadia
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    Mcintyre, Kristi
    Wei, Ran
    Antonio, Belen San
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Tolaney, Sara M.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 31 - 31
  • [27] Patients' quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, S.
    Blancas, I.
    Im, Y. -H.
    Rastogi, P.
    Brown, J.
    Shahir, A.
    Zimmermann, A.
    Boyle, F.
    BREAST, 2021, 56 : S20 - S21
  • [28] Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review
    de Mello Morais Mata, Danilo Giffoni
    Carmona, Carlos Amir
    Eisen, Andrea
    Trudeau, Maureen
    CURRENT ONCOLOGY, 2022, 29 (07) : 4956 - 4969
  • [29] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
    Ma, S. J.
    Oladeru, O. T.
    Sood, A. J.
    Mikucki, M.
    Farrugia, M. K.
    Singh, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
  • [30] New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
    Jamie O. Brett
    Erica L. Mayer
    Current Treatment Options in Oncology, 2023, 24 : 594 - 610
12345